Mandate

Vinge advises in conjunction with sale of Powerbox

June 27, 2018 M&A

Vinge has advised the sellers, including Alder and Industrifonden, in conjunction with the sale of a majority stake in Powerbox International AB.

Powerbox has subsidiaries in 15 countries and a turnover of more than MSEK 400. With its design divisions at its head office in Gnesta, in Germany and in the Netherlands, as well as the local sales companies in Europe, the United States, China and Australia, the company offers development and manufacture of standard and bespoke customer power supply solutions for exacting applications within the industrial, medical technology, vehicles and defence sectors.

The buyer is Cosel Co, Ltd., a Japanese company listed on the Tokyo stock exchange. Cosel is one of the worlds’ leading manufacturers of high performance AC/DC, DC/DC transformers and related EMC filters.

Vinge’s team primarily consisted of partner Johan Larsson together with, among others, associates Samra Baytar, Martin Cronsioe and Sofie Sundin.
 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025